Novanta INC 8-K filings

Novanta Inc. announced robust financial results for the second quarter of 2026, exceeding expectations with significant revenue and Adjusted EBITDA growth, and provided strong guidance for the remainder of the year.

Novanta Inc. has finalized its acquisition of Riverpoint Medical for approximately $1.2 billion, significantly expanding its medical consumables business and recurring revenue.

Novanta Inc. announced its definitive agreement to acquire Riverpoint Medical for $1.2 billion in cash plus a $250 million milestone payment, aiming to accelerate its strategic shift towards recurring revenue in the minimally invasive surgery sector.

Novanta Inc. shareholders re-elected all nine director nominees and approved executive compensation and auditor appointments at the 2026 Annual Meeting.

Novanta Inc. has amended its credit agreement to establish a $200 million delayed draw term loan facility maturing in 2030.

Novanta Inc. announced its first quarter 2026 financial results, showcasing a 10% increase in GAAP revenue to $257.7 million and a 14% rise in Adjusted EBITDA to $57 million.

Novanta Inc. reported strong fourth-quarter 2025 financial results, exceeding revenue expectations with 9% growth and outlining plans for continued momentum and strategic acquisitions in 2026.

Novanta Inc. announced the appointment of Alexander Manganiello as its new General Counsel and Corporate Secretary, effective December 1, 2025.

Novanta Inc. has revised its fourth quarter and full year 2025 non-GAAP adjusted diluted earnings per share guidance downwards following a recent equity issuance.

Novanta Inc. announced the pricing of 12.65 million tangible equity units at $50.00 each, raising $632.5 million, and amended its credit agreement to increase leverage flexibility.

Novanta Inc. reported third-quarter 2025 financial results exceeding revenue, profit, and Adjusted EPS expectations, driven by Advanced Surgery growth and new product revenues.

Barbara Hulit has resigned from Novanta Inc.'s Board of Directors and its Audit and ESG Committees, effective November 1, 2025.

Novanta Inc.'s Board of Directors authorized an additional $200 million for its share repurchase program, bringing the total available capacity to $231 million.

Novanta Inc. reported solid second-quarter 2025 financial results, with GAAP revenue up 2% to $241 million and updated full-year guidance.

Novanta Inc. announced the departure of Michele D. Welsh from her roles as General Counsel and Corporate Secretary, effective July 18, 2025.

Novanta Inc. has entered into a new $1.0 billion credit agreement, replacing its existing facility and extending its debt maturity to June 2030, enhancing financial flexibility.

Novanta Inc. announced a comprehensive 2025 Restructuring Plan, commencing in June 2025, to streamline operations and achieve approximately $20 million in annualized cost savings, despite incurring estimated pre-tax charges of $20 million to $25 million.

Novanta Inc. announced that its shareholders overwhelmingly approved all proposals at its annual general meeting, including the election of all director nominees, executive compensation, and the annual frequency for future executive compensation votes.

Novanta reports a slight revenue increase and a significant jump in net income for the first quarter of 2025, while reaffirming its full-year Adjusted EBITDA guidance.

Novanta Inc. announces a realignment of its financial reporting structure into two segments, Automation Enabling Technologies and Medical Solutions, and provides recast historical segment data for 2023 and 2024.

Novanta Inc. announces positive financial results for Q4 and full year 2024, with revenue increasing by 13% in the fourth quarter and 8% for the full year.

Novanta Inc. announced its third quarter 2024 financial results, showcasing revenue growth and positive momentum from new product launches.

Novanta Inc. has appointed John Burke as its new Chief Accounting Officer, succeeding Peter Chang, who will transition out of the role by February 2025.

Novanta announced its second quarter 2024 financial results, exceeding expectations with $236 million in revenue and $13.8 million in net income.

Novanta Inc. has announced that its Chief Human Resources Officer, Brian Young, will be departing from his role effective November 1, 2024, or an earlier agreed upon date.

Novanta Inc. reports the resignation of Katherine A. Owen from the Board of Directors and the appointment of Mary Kay Ladone to fill the vacancy, both effective July 11, 2024.

Novanta Inc. successfully held its annual general meeting, electing all director nominees and approving the executive compensation and auditor appointment proposals.

Novanta announced its first quarter 2024 financial results, reporting revenue of $231 million and adjusted earnings per share of $0.74, surpassing expectations.

Novanta Inc. has replaced PricewaterhouseCoopers LLP (PwC) with Deloitte & Touche LLP as its independent registered public accounting firm, effective March 14, 2024.

Novanta Inc. announced its financial results for the fourth quarter and full year 2023, highlighting record full-year revenue and providing a positive outlook for 2024.